Specifically, only the presence of the KIR2DL1/C2-ligand interaction was associated with lower 5y-EFS rates (80.0% vs. 96.5%, p = 0.032) in total patients (Figure 4A left, B), as well as in B-ALL (84.8% vs. 95.8%, n.s.), T-ALL (80.0% vs. 100%, n.s.)and AML (64.3% vs. 100%, n.s.)(Figure 4B). This evidence concerns the gene KIR2DL1 and acute myeloid leukemia.